Fundraising FoxRegenacy Pharmaceuticals
Waltham, US · Founded 2016 · Delaware corporation · 4 known investors
Find your way into Regenacy Pharmaceuticals
Each arrow is one introduction. Sign up to fill in the first one.
16 people can intro you to Marc
Ask Thomas Needham to introduce you to Marc Cohen
You →Thomas · together at C4 Therapeutics →Marc
Sign up to find every way you can get introduced to Regenacy Pharmaceuticals
- Your email: who you already know at Regenacy Pharmaceuticals, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Regenacy Pharmaceuticals team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Founders & leadership
SJ
Simon JonesPresident and Chief Executive Officer
MC
JR
John RochaChief Financial Officer
ML
Michael L. HuangNamed on SEC filing
WC
William ChinNamed on SEC filing
SY
Shixiang YanNamed on SEC filing
DW
Daguang WangNamed on SEC filing
Investors · 4
3E Bioventures CapitalreportedPalo Alto
How we know: a partner's Signal profile · markets.financialcontent.com · Not right? Tell us
Cobro VenturesreportedMclean
How we know: funding news · markets.financialcontent.com · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$28.7M disclosed across 2 rounds · 2020–2022
▶$7.8MraisedFeb 2022 · 9 investors · PharmaceuticalsRule 506(b)
▶$7.8MraisedFeb 2022 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Daguang WangDirector
- William ChinDirector
- Simon JonesExecutive Officer, Director
- Shixiang YanDirector
- Michael L. HuangDirector
- Marc CohenExecutive Officer, Director
- John RochaExecutive Officer
- Offering amount
- $10M
- Amount sold
- $7.8M
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.9MraisedApr 2020 · 19 investors · PharmaceuticalsRule 506(b)
▶$20.9MraisedApr 2020 · 19 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael L. HuangDirector
- Simon JonesExecutive Officer, Director
- William ChinDirector
- Shixiang YanDirector
- Daguang WangDirector
- Marc CohenExecutive Officer, Director
- John RochaExecutive Officer
- Offering amount
- $40.7M
- Amount sold
- $20.9M
- Sales commissions
- $757.5K
- Placement agents
- Locust Walk Partners, LLC
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Regenacy Pharmaceuticals's investors?
- Regenacy Pharmaceuticals's investors include 3E Bioventures Capital, Cobro Ventures, Taiwania Capital, Yonjin Venture LLC.
- How much funding has Regenacy Pharmaceuticals raised?
- Regenacy Pharmaceuticals has disclosed $28.7M raised across 2 rounds.
- Where is Regenacy Pharmaceuticals headquartered?
- Regenacy Pharmaceuticals is headquartered in Waltham, US.